Survival analysis revealed that HTATSF1-depleted breast cancer cells were more susceptible to chemotherapeutic treatment, including cisplatin, CPT, rucaparib, and talazoparib (Fig. 3F), whereas the additive effect was not detected in HMECs (Fig. 3G), indicating that HTATSF1 loss resulted in tumor cell–specific vulnerability to chemotherapeutic drugs. This evidence concerns the gene HTATSF1 and breast cancer.